Pazopanib - dilemmas in kidney cancer treatment
Journal Title: OncoReview - Year 2013, Vol 3, Issue 4
Abstract
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in initial therapy where there are few drugs with similar properties. The choice of drug in first line is based on prognostic factors and clinical profiles of drug and patient. Important are also patient’s expectations connected with treatment. COMPARZ trail shows results of comparison between sunitinib and pazopanib which both are given in first line treatment of mRCC. Based on this the decision of choosing proper drug seems to be easier.
Authors and Affiliations
Piotr Tomczak
The influence of socio-demographic factors on making a decision related to the disease and treatment in women with breast cancer
Introduction. Socio-demographic factors may affect the decision making associated with the disease and the long-term results of treatment.Objective. Exploring the relationship between socio-demographic factors of women t...
Mitral regurgitation after anthracycline exposure: a case report
We report the case of a 66-year-old African American female with a history of breast cancer previously treated with anthracycline based chemotherapy presenting with significant mitral regurgitation. She initially had pre...
Delayed anthracycline-induced cardiomyopathy – case report
43-year-old man was admitted to the hematology department due to second recurrence of anaplastic lymphoma T-cell ALK+. Lymphoma was diagnosed 28 years earlier. The patient received COP regimen (17 cycles) and CHOP (5 cyc...
Tuberus sclerosis
Zaburzenia psychiczne u chorych na nowotwory - podejście kliniczne
Pacjent z chorobą nowotworową nie tylko mierzy się z chorobą pierwotną, ale także narażony jest na stany emocjonalne, które przy niesprzyjających warunkach i dużym obciążeniu mogą prowadzić do depresji, zwiększonego lęku...